President Donald Trump signed an executive order this week setting a 30-day deadline for drugmakers to electively lower prices in the U.S. or face new limits on what the government will pay.

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday. Trump's order, signed on Monday, directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations.

The executive order directs Trump's administration to take actions against "discriminatory" policies in foreign countries that suppress drug prices.